A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: ACR16
OTHER: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.